Jason J. Rose, MD, MBA - Chief Executive Officer
Jesus Tejero, PhD - Chief Scientific Officer
Xueli Wang, MBA - Chief Financial Officer
Anthony DeMartino, PhD - Research Director
Dr. DeMartino earned his B.S. in chemistry from Wake Forest University and his Ph.D. in chemistry from the University of California, Santa Barbara in 2017 where he specialized in bioinorganic reaction mechanisms, chemical synthesis, and reaction kinetics involving small bioregulation molecules like nitric oxide (NO) and carbon monoxide (CO). In 2018, he joined Dr. Mark Gladwin’s group at the University of Pittsburgh for his postdoctoral work, where he focuses on the chemistry and translational research of heme-based proteins and models and their interactions with NO, CO, and nitrite. His current research interests specifically include a) the activation and metabolism of inorganic nitrite by hemoproteins; b) the determination of native substrates, redox chemistry, and functions of the hemoproteins cytoglobin and neuroglobin; c) and the development of hemoprotein-based therapeutics for CO poisoning. Dr. DeMartino joined Globin Solutions as a Research Director in 2021.
Lindsey Bocian - Program Administrator
Lindsey Bocian joined the team as Program Administrator in March 2021. She earned her B.S. in Biology from Gannon University in 2011. She has experience as a project manager, laboratory manager, and laboratory technician.
Regulatory Experts at PharmaDirections
Ed Branson, PhD - CMC Expert Biologics
Dr. Ed Branson is an experienced CMC operations executive who led the daily operations of seven GMP manufacturing organizations including cell culture, fermentation, vaccine and trans-dermal patch, transgenic plant, combination pulmonary drug/device and regenerative tissue manufacturing facilities. He managed pilot plants, directed production from preclinical through Phase III and brought five manufacturing facilities into GMP compliance.
Tilmann Brotz, Phd - Strategic Program Lead, Non-clinical Expert
Dr. Tilmann Brotz is a senior Development Sciences Consultant with over 15 years of experience in the biopharmaceutical industry leading toxicology, DMPK, in-vivo pharmacology, clinical pharmacology and diagnostic groups. He also has extensive experience with multiple clinical biomarker modalities (blood, histology, FDGPET and CT imaging). He is a CLSI FAST advisor and a member of the Scientific Review Board of the Alzheimer’s Drug Discovery Foundation.
Andrew Nicholls, PhD - Clinical Pharmacologist and Medical Monitor
Dr. Andrew Nicholls is a pharmaceutical physician with experience across a wide range of therapeutic areas and has a passion for scientiﬁcally–driven, eﬃcient drug development. He establishes productive working relationships in project teams with investigators and vendors. Eﬀective in medical writing and presentation of data, skilled in the use of data visualization methods and management of PK/PD analysis leading to persuasive and eﬃcient analyses of exploratory studies. Collaboration with Investigators and KOLs has resulted in eﬃcient, rigorous conduct of clinical studies and creativity in strategic planning. Strong clinical pharmacology background and familiarity with analytic tools ensures pharmacologically-driven protocol, program design and analysis. Designed and managed multiple ﬁrst-in-human studies, Phase I supportive studies, POC, dose response studies, and demonstration of eﬃcacy studies including large scale Phase II evaluations.
Mary Sherman, Ph.D - DMPK/Bioanalytical Expert
Dr. Mary Sherman is a skilled scientific advisor and program manager for late-stage Discovery through Phase III of drug development. She manages programs/studies from late-stage Discovery through Phase III, including bioanalytical, drug metabolism, PK/TK, immunogenicity and regulatory requirements. Additionally she provides support to both nonclinical and clinical studies. Dr. Sherman has a strong reputation for critical thinking, relationship building, social intelligence, and clear communications that establishes bridges between scientific and non-scientific stakeholder coupled with a proven analysis and strategic perspective combined with marketing, operations, and R&D integration.
Christy Damphousse - Project Manager
Ms. Damphousse has 20 years of experience in the biopharmaceutical industry with special training in Biotechnology Project Management. She has managed projects for Pharmadirections for over 7 years including support of both CMC and nonclinical IND enabling activities for small molecules and biologics. She provides project momentum to meet milestones through vendor, timeline, budget and meeting management. Ms. Damphousse also has 10 years of experience as an R&D scientist in both start-ups and big pharma.